Spironolactone-d3-1

Spironolactone-d3-1

• UNSPSC Description: Spironolactone-d3-1 is deuterium labeled Spironolactone. Spironolactone (SC9420) is an orally active aldosterone mineralocorticoid receptor antagonist with an IC50 of 24 nM. Spironolactone is also a potent antagonist of androgen receptor with an IC50 of 77 nM. Spironolactone promotes autophagy in podocytes[1][2][3].
• Target Antigen: Androgen Receptor; Autophagy; Isotope-Labeled Compounds; Mineralocorticoid Receptor
• Type: Isotope-Labeled Compounds
• Related Pathways: Autophagy;Metabolic Enzyme/Protease;Others;Vitamin D Related/Nuclear Receptor
• Applications: Metabolism-sugar/lipid metabolism
• Field of Research: Metabolic Disease; Cancer
• Solubility: 10 mM in DMSO
• Smiles: C[C@@]12[C@](OC3=O)(CC3)CC[C@@]1([H])[C@@]([C@@H](CC4=C([2H])C5=O)SC(C)=O)([H])[C@]([C@]4(CC5([2H])[2H])C)([H])CC2
• Molecular Weight: 419.59
• References & Citations: [1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216.|[2]Dong D, et al. Spironolactone alleviates diabetic nephropathy through promoting autophagy in podocytes. Int Urol Nephrol. 2019;51(4):755-764.|[3]Fagart J, et al. A new mode of mineralocorticoid receptor antagonism by a potent and selective nonsteroidal molecule. J Biol Chem. 2010;285(39):29932-29940.|[4]Kim GK, et al. Oral Spironolactone in Post-teenage Female Patients with Acne Vulgaris: Practical Considerations for the Clinician Based on Current Data and Clinical Experience. J Clin Aesthet Dermatol. 2012;5(3):37-50.
• Shipping Conditions: Room temperature
• Clinical Information: No Development Reported